Italia markets closed
Dow Jones
38.868,04 +69,05 (+0,18%) Nasdaq
17.192,53 +59,40 (+0,35%) Nikkei 225
39.038,16 +354,23 (+0,92%) EUR/USD
1,0767 -0,0037 (-0,34%) Bitcoin EUR
64.623,72 -70,41 (-0,11%) CMC Crypto 200
1.437,20 -9,47 (-0,65%)
SWTX Jun 2024 55.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 01:44PM EDT. Mercato aperto.
| Chiusura precedente | 10,30 |
| Aperto | 10,30 |
| Denaro | 8,10 |
| Domanda | 11,30 |
| Prezzo d'esercizio | 55,00 |
| Scadenza | 2024-06-21 |
| Min-Max giorno | 10,30 - 10,30 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 5 |
GlobeNewswireSpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
– Presented additional Phase 3 DeFi data at ASCO demonstrating clinically significant reductions in pain and substantial reductions in tumor volume and T2 hyperintensity with nirogacestat treatment – – Completed enrollment of Phase 2 trial evaluating nirogacestat in patients with ovarian granulosa cell tumors – – Highlighted encouraging Phase 1 and 2 clinical data from emerging pipeline programs at AACR and EHA – STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (
© 2024 Yahoo. Tutti i diritti riservati.